Lurbinectedin Clinical Trials (2026): 54 Studies for Small Cell Lung Cancer & Advanced Solid Tumor
Hipa.ai Research · Source: ClinicalTrials.gov / AACT
Synced daily from ClinicalTrials.gov via AACT. Last sync: .
54 Lurbinectedin clinical trials are catalogued on Hipa.ai from the AACT mirror of ClinicalTrials.gov, spanning 36 indications (including Small Cell Lung Cancer & Advanced Solid Tumor) and 7,571 total planned enrollment. 9 Phase 3 Lurbinectedin trials and 19 Phase 2 are listed. 21 Lurbinectedin clinical trials are actively recruiting at 66 U.S. sites across 24 states. Most recent activity: NCT07155174 (Sep 2031).
Where to Participate: All Lurbinectedin Trial Sites in the U.S. (66 sites across 24 states)
Every actively recruiting Lurbinectedintrial site, sorted by state then city. Each row links to the trial detail page (eligibility, contacts, full study record). Sites no longer enrolling at the location level are excluded. ClinicalTrials.gov / AACT does not provide street-level addresses; the map link uses the facility's geocoded coordinates where available.
| State | Facility | City | Trial | Map |
|---|---|---|---|---|
| AR | Highlands Oncology Group | Springdale72762 | NCT06203210 | Map |
| CA | Clinical Research Providence Medical Foundation | Fullerton92835 | NCT06203210 | Map |
| CA | Cedars-Sinai Medical Center | Los Angeles90048 | NCT05918640 | Map |
| CA | Children's Hospital of Los Angeles | Los Angeles90027 | NCT05734066 | Map |
| CA | UCLA Hematology-Oncology | Los Angeles90095 | NCT06203210 | Map |
| CA | Lucile Packard Children's Hospital | Palo Alto94304 | NCT05734066 | Map |
| CA | VA Palo Alto Health Care System, Palo Alto, CA | Palo Alto94304-1207 | NCT06681220 | Map |
| CA | UCSF Mission Bay Mission Hall | San Francisco94115 | NCT06203210 | Map |
| CA | Sarcoma Oncology Research Center | Santa Monica90403 | NCT05876715 | Map |
| CT | Yale University School of Medicine /ID# 278181 | New Haven06510 | NCT07155174 | Map |
| DC | Children's National Hospital | Washington D.C.20010 | NCT05734066 | Map |
| FL | University of Miami Hospital and Clinics Sylvester Comprehensive Cancer Center | Miami33136 | NCT06203210 | Map |
| FL | Ocala Oncology Center /ID# 278269 | Ocala34474 | NCT07155174 | Map |
| FL | AdventHealth Orlando, Cancer Institute | Orlando32804 | NCT06203210 | Map |
| FL | Johns Hopkins All Children's Hospital | St. Petersburg33701 | NCT05734066 | Map |
| FL | Moffitt Cancer Center /ID# 277573 | Tampa33612 | NCT07155174 | Map |
| GA | Children's Healthcare of Atlanta at Arthur M. Blank Hospital | Atlanta30329 | NCT05734066 | Map |
| GA | Emory University | Atlanta30322 | NCT05244239 | Map |
| IL | Rush MD Anderson Cancer Center | Chicago60612 | NCT06203210 | Map |
| IN | Fort Wayne Medical Oncology And Hematology /ID# 277336 | Fort Wayne46804 | NCT07155174 | Map |
| IN | Richard L. Roudebush VA Medical Center, Indianapolis, IN | Indianapolis46202-2884 | NCT06681220 | Map |
| IA | University of Iowa Hospitals and Clinics | Iowa City52242 | NCT05918640 | Map |
| KY | Baptist Health Lexington | Lexington40503 | NCT06203210 | Map |
| KY | Baptist Health Lexington /ID# 277729 | Lexington40503 | NCT07155174 | Map |
| MD | John Hopkins School of Medicine | Baltimore21287 | NCT06203210 | Map |
| MD | Johns Hopkins University | Baltimore21238 | NCT05734066 | Map |
| MD | University of Maryland Greenebaum Comprehensive Cancer Center | Baltimore21201 | NCT06203210 | Map |
| MD | National Institutes of Health Clinical Center | Bethesda20892 | NCT06228066 | Map |
| MA | Dana-Farber Cancer Institute | Boston02215 | NCT05918640 | Map |
| MA | Dana-Farber Cancer Institute | Boston02216 | NCT06203210 | Map |
| MA | Dana-Farber Cancer Institute /ID# 277732 | Boston02215 | NCT07155174 | Map |
| MI | University of Michigan | Ann Arbor48109 | NCT05918640 | Map |
| MI | Corewell Health | Grand Rapids49503 | NCT05734066 | Map |
| MO | Mercy Clinic Oncology and Hematology Sindelar Cancer Center | St Louis63128 | NCT06203210 | Map |
| NE | University of Nebraska Medical Center | Omaha68198-6811 | NCT06203210 | Map |
| NH | Dartmouth-Hitchcock Medical Center | Lebanon03766 | NCT06203210 | Map |
| NJ | Astera Cancer Care | East Brunswick08816 | NCT06203210 | Map |
| NJ | Hackensack Meridian Health Jsumc | Neptune City07753 | NCT06203210 | Map |
| NY | Clinical Research Alliance, Inc | Lake Success11042 | NCT06203210 | Map |
| NY | Laura and Isaac Perlmutter Cancer Center at NYU Langone Health Long Island | New York10016 | NCT06203210 | Map |
| NY | Memorial Sloan Kettering Cancer Center | New York10065 | NCT05734066 | Map |
| NY | Memorial Sloan Kettering Cancer Center | New York10065 | NCT05918640 | Map |
| NY | New York University Cancer Center - Laura and Isaac | New York10016 | NCT06203210 | Map |
| NC | Lineberger Comprehensive Cancer Center at University of North Carolina Chapel Hill | Chapel Hill27599 | NCT05578326 | Map |
| NC | Salisbury W.G. (Bill) Hefner VA Medical Center, Salisbury, NC | Salisbury28144 | NCT06681220 | Map |
| OH | Cleveland Clinic Mercy Hospital | Canton44708 | NCT06203210 | Map |
| OH | Cincinnati Children's Hospital Medical Center | Cincinnati45229 | NCT05734066 | Map |
| OH | Oncology/Hematology Care Clinical Trials, Llc | Cincinnati45236 | NCT06203210 | Map |
| OH | University Hospitals Cleveland Medical Center /ID# 277556 | Cleveland44106 | NCT07155174 | Map |
| OH | Nationwide Children's Hospital | Columbus43205 | NCT05734066 | Map |
| PA | Children's Hospital of Philadelphia | Philadelphia19104 | NCT05734066 | Map |
| PA | Children's Hospital of Philadelphia | Philadelphia19104 | NCT05918640 | Map |
| PA | Corporal Michael J. Crescenz VA Medical Center, Philadelphia, PA | Philadelphia19104-4551 | NCT06681220 | Map |
| PA | Fox Chase Cancer Center | Philadelphia19111 | NCT05800587 | Map |
| PA | VA Pittsburgh Healthcare System University Drive Division, Pittsburgh, PA | Pittsburgh15240 | NCT06681220 | Map |
| TN | THE WEST CLINIC, PLLC dba West Cancer Center | Germantown38138 | NCT06203210 | Map |
| TN | St. Jude Children's Research Hospital | Memphis38105 | NCT05734066 | Map |
| TX | Children's Health Dallas | Dallas75235 | NCT05734066 | Map |
| TX | Houston Methodist Cancer Center | Houston77030 | NCT06203210 | Map |
| TX | M D Anderson Cancer Center | Houston77030 | NCT05636111 | Map |
| TX | Michael E. DeBakey VA Medical Center, Houston, TX | Houston77030-4211 | NCT06681220 | Map |
| TX | The University of Texas MD Anderson Cancer Center | Houston77030 | NCT05734066 | Map |
| TX | The University of Texas MD Anderson Cancer Center /ID# 277929 | Houston77030 | NCT07155174 | Map |
| TX | University of Texas Md Anderson Cancer Center | Houston77030 | NCT06203210 | Map |
| TX | Texas Oncology, P.A. - Tyler | Tyler75702 | NCT06203210 | Map |
| VA | Virginia Cancer Specialists - Fairfax /ID# 278298 | Fairfax22031 | NCT07155174 | Map |
Lurbinectedin clinical trials at a glance: phase × recruitment status
| Phase | recruiting | active not recruiting | enrolling by invitation | completed | terminated | withdrawn | not yet recruiting | unknown | approved for marketing | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| P1 | 2 | 7 | 1 | 1 | 11 | |||||
| P1/P2 | 4 | 2 | 2 | 3 | 2 | 13 | ||||
| P2 | 6 | 1 | 1 | 5 | 1 | 2 | 3 | 19 | ||
| P3 | 2 | 3 | 3 | 1 | 9 | |||||
| N/A | 1 | 1 | 2 |
Recruiting Lurbinectedin clinical trials (21)
Studies currently enrolling participants. Click any NCT ID to view the trial detail page (eligibility, sites, contacts).
| NCT ID | Title | Phase | Indication | Enrollment | Started |
|---|---|---|---|---|---|
| NCT07155174 | SEZanneA Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination With Atezolizumab Versus Standard of Care as First-Line Treatment in Adult Participants With Previously Untreated Extensive Stage Small Cell Lung Cancer | P2 | Small Cell Lung Cancer | 180 | Nov 2025 |
| NCT06681220 | Relapsed SCLCBiomarker Directed Trial of Temozolomide and Stenoparib in Relapsed SCLC | P1/P2 | Relapsed Small Cell Lung Cancer | 166 | Feb 2026 |
| NCT07141771 | An Umbrella Study of Recurrent, Extensive Stage Small Cell Lung Cancer Based on Molecular Typing | P1/P2 | SCLC, Extensive Stage | 100 | Dec 2025 |
| NCT07328425 | ISG-TULIPSClinical Study in Adult and Young Adult Patients With Advanced Desmoplastic Small Round Cell Tumor (DSRCT) ISG-TULIPS | P2 | Desmoplastic Small Round Cell Tumor | 20 | Nov 2025 |
| NCT07365241 | A Study to Evaluate Adverse Events and Change in Disease Activity of Intravenous ABBV-706 Versus Standard of Care in Adult Participants With Relapsed/Refractory Small Cell Lung Cancer | P3 | Small Cell Lung Cancer | 531 | Apr 2026 |
| NCT07121478 | Patients With High-grade Pancreatic Neuroendocrine Tumors | P2 | Neuroendocrine Tumor of Pancreas | 46 | Sep 2025 |
| NCT07153055 | LOTSLurbinectedin With Osimertinib in Transformed Small Cell Lung Cancer | P1/P2 | Small Cell Lung Cancer ( SCLC ) | 16 | May 2026 |
| NCT05800587 | Dose Attenuated Chemotherapy in Compromised Patients With Lung Cancer | P2 | Lung Cancer | 280 | Feb 2023 |
| NCT06203210 | IDeate-Lung02A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer | P3 | Small Cell Lung Cancer | 540 | May 2024 |
| NCT07258147 | Safety and Efficacy of Radiotherapy Combined With Immunochemotherapy in Pre-treated SCLC Patients With Liver Metastases | P2 | Lung Cancer (SCLC) | 30 | Oct 2026 |
| NCT05578326 | Study of Trilaciclib and Lurbinectidin | P2 | Lung Cancer | 30 | Oct 2022 |
| NCT06228066 | LASERLurbinectedin With or Without Avelumab in Small Cell Carcinoma of the Bladder (LASER) | P2 | Small Cell Carcinoma of the Bladder | 45 | Jun 2024 |
| NCT05918640 | LiFFTLurbinectedin in FET-Fused Tumors | P1/P2 | Ewing Sarcoma | 63 | Jul 2023 |
| NCT06496048 | Lurbinectedin or in Combination with Irinotecan Versus Topotecan in Patients with Relapsed SCLC | P3 | Relapsed Small Cell Lung Cancer | 180 | Sep 2024 |
| NCT07459634 | A Study of Lurbinectedin in Combination With Durvalumab for the Treatment of Participants With ES-SCLC | P2 | Extensive-stage Small-cell Lung Cancer | 50 | Jun 2026 |
| NCT05734066 | Study of Lurbinectedin Monotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Ewing Sarcoma | P1/P2 | Refractory Ewing Sarcoma | 60 | May 2023 |
| NCT05244239 | Palliative Radiotherapy With Lurbinectedin in Patients With Extensive Stage Small Cell Lung Cancer | P1 | Extensive Stage Lung Small Cell Carcinoma | 22 | Jul 2022 |
| NCT06497530 | Maintenance Lurbinectedin in Combination With Serplulimab for Patients With ES-SCLC | P2 | Extensive-Stage Small Cell Lung Cancer | 30 | Dec 2024 |
| NCT05636111 | Phase 1b of Lurbinectedin in Combination With Weekly Paclitaxel and Bevacizumab in Platinum-resistant Ovarian Cancer | P1 | Ovarian Cancer | 34 | Jul 2023 |
| NCT05876715 | LINNOVATELINNOVATE: Lurbinectedin, Ipilimumab and Nivolumab for Soft Tissue Sarcoma | P1/P2 | Advanced Soft-tissue Sarcoma | 40 | Jun 2023 |
| NCT06501976 | An Exploratory Study of Lurbinectedin With Radiotherapy in Locally-advanced SCLC After First-line Therapy | P2 | Small Cell Lung Carcinoma | 9 | Jul 2024 |
Lurbinectedin clinical trials by indication
Small Cell Lung Cancer (5)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07155174 | SEZanne | P2 | recruiting | A Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination With Atezolizumab Versus Standard of Care as First-Line Treatment in Adult Participants With Previously Untreated Extensive Stage Small Cell Lung Cancer |
| NCT07365241 | — | P3 | not yet recruiting | A Study to Evaluate Adverse Events and Change in Disease Activity of Intravenous ABBV-706 Versus Standard of Care in Adult Participants With Relapsed/Refractory Small Cell Lung Cancer |
| NCT06203210 | IDeate-Lung02 | P3 | recruiting | A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer |
| NCT05572476 | LURBIMUNE | P2 | withdrawn | Lurbinectedin Combined With Durvalumab in Pre-treated Patients With Extensive Stage Small-cell Lung Cancer |
| NCT04291937 | — | N/A | approved for marketing | A Multicenter Expanded Access Treatment Protocol of Lurbinectedin in Previously Treated SCLC in the USA |
Advanced Solid Tumor (4)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05101265 | — | P1 | unknown | Clinical Pharmacokinetic Study of Lurbinectedin in Patients With Advanced Solid Tumors and Varying Degrees of Hepatic Impairment |
| NCT05126433 | JAZZ EMERGE201 | P2 | terminated | Lurbinectedin Monotherapy in Participants With Advanced or Metastatic Solid Tumors |
| NCT04638491 | — | P1 | completed | Safety Tolerability Pharmacokinetic and Preliminary Efficacy in Chinese Advanced Solid Tumors Patients |
| NCT05072106 | — | P1 | completed | Study to Evaluate the Effect of Bosentan on the Pharmacokinetics of Lurbinectedin in Patients With Advanced Solid Tumors |
Advanced Solid Tumors (4)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02611024 | — | P1/P2 | completed | Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid Tumors |
| NCT05063318 | PM01183 | P1 | completed | Clinical Trial of Lurbinectedin (PM01183) in Patients With Advanced Solid Tumors |
| NCT02454972 | PM01183 | P2 | completed | Clinical Trial of Lurbinectedin (PM01183) in Selected Advanced Solid Tumors |
| NCT01980667 | PM01183 | P1 | completed | Study of Lurbinectedin (PM01183) in Combination With Cisplatin in Patients With Solid Tumors |
Relapsed Small Cell Lung Cancer (3)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06681220 | Relapsed SCLC | P1/P2 | recruiting | Biomarker Directed Trial of Temozolomide and Stenoparib in Relapsed SCLC |
| NCT06496048 | — | P3 | recruiting | Lurbinectedin or in Combination with Irinotecan Versus Topotecan in Patients with Relapsed SCLC |
| NCT05153239 | LAGOON | P3 | completed | Clinical Trial of Lurbinectedin as Single-agent or in Combination With Irinotecan Versus Topotecan or Irinotecan in Patients With Relapsed Small-cell Lung Cancer (LAGOON) |
Small-cell Lung Cancer (3)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04610658 | — | P1 | terminated | Immune Checkpoint Inhibition With Lurbinectedin Relapsed/Recurrent SCLC |
| NCT05285033 | LURBICLIN | N/A | completed | RW Effectiveness of Lurbinectedin in Extensive Stage SCLC |
| NCT02566993 | ATLANTIS | P3 | completed | Clinical Trial of Lurbinectedin (PM01183)/Doxorubicin Versus CAV or Topotecan as Treatment in Patients With Small-Cell Lung Cancer |
Small Cell Lung Carcinoma (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06501976 | — | P2 | not yet recruiting | An Exploratory Study of Lurbinectedin With Radiotherapy in Locally-advanced SCLC After First-line Therapy |
| NCT04358237 | LUPER | P1/P2 | completed | Lurbinectedin (PM01183) Combined With Pembrolizumab in Small Cell Lung Cancer. |
Ovarian Cancer (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05636111 | — | P1 | recruiting | Phase 1b of Lurbinectedin in Combination With Weekly Paclitaxel and Bevacizumab in Platinum-resistant Ovarian Cancer |
| NCT02421588 | CORAIL | P3 | completed | Clinical Trial of Lurbinectedin (PM01183) in Platinum Resistant Ovarian Cancer Patients |
Advanced Soft-tissue Sarcoma (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05099666 | — | P1/P2 | active not recruiting | Lurbinectedin + Doxorubicin In Leiomyosarcoma |
| NCT05876715 | LINNOVATE | P1/P2 | recruiting | LINNOVATE: Lurbinectedin, Ipilimumab and Nivolumab for Soft Tissue Sarcoma |
Lung Cancer (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05800587 | — | P2 | recruiting | Dose Attenuated Chemotherapy in Compromised Patients With Lung Cancer |
| NCT05578326 | — | P2 | recruiting | Study of Trilaciclib and Lurbinectidin |
Small Cell Lung Cancer ( SCLC ) (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07153055 | LOTS | P1/P2 | not yet recruiting | Lurbinectedin With Osimertinib in Transformed Small Cell Lung Cancer |
Extensive-stage Small-cell Lung Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07459634 | — | P2 | not yet recruiting | A Study of Lurbinectedin in Combination With Durvalumab for the Treatment of Participants With ES-SCLC |
SCLC, Extensive Stage (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07141771 | — | P1/P2 | not yet recruiting | An Umbrella Study of Recurrent, Extensive Stage Small Cell Lung Cancer Based on Molecular Typing |
Lung Cancer (SCLC) (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07258147 | — | P2 | not yet recruiting | Safety and Efficacy of Radiotherapy Combined With Immunochemotherapy in Pre-treated SCLC Patients With Liver Metastases |
Desmoplastic Small Round Cell Tumor (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07328425 | ISG-TULIPS | P2 | recruiting | Clinical Study in Adult and Young Adult Patients With Advanced Desmoplastic Small Round Cell Tumor (DSRCT) ISG-TULIPS |
Neuroendocrine Tumor of Pancreas (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07121478 | — | P2 | enrolling by invitation | Patients With High-grade Pancreatic Neuroendocrine Tumors |
Locally Advanced Soft Tissue Sarcoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06217536 | — | P1/P2 | withdrawn | Neoadjuvant Lurbinectedin and Preoperative Radiation for Treating Soft Tissue Sarcomas |
Extensive-Stage Small Cell Lung Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06497530 | — | P2 | recruiting | Maintenance Lurbinectedin in Combination With Serplulimab for Patients With ES-SCLC |
Small Cell Carcinoma of the Bladder (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06228066 | LASER | P2 | recruiting | Lurbinectedin With or Without Avelumab in Small Cell Carcinoma of the Bladder (LASER) |
Endometrial Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06385548 | LiDer | P1/P2 | withdrawn | Efficacy and Safety Study of Lurbinectedin and Dostarlimab in Cancer Patients: Protocol VHIO21001 - LiDer |
Leiomyosarcoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06088290 | SaLuDo | P3 | active not recruiting | Study of Lurbinectedin in Combination With Doxorubicin Versus Doxorubicin Alone as First-line Treatment in Participants With Metastatic Leiomyosarcoma (SaLuDo) |
Ewing Sarcoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05918640 | LiFFT | P1/P2 | recruiting | Lurbinectedin in FET-Fused Tumors |
Small Cell Lung Cancer (SCLC) (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05740566 | DeLLphi-304 | P3 | active not recruiting | Study Comparing Tarlatamab With Standard of Care Chemotherapy in Relapsed Small Cell Lung Cancer |
Refractory Ewing Sarcoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05734066 | — | P1/P2 | recruiting | Study of Lurbinectedin Monotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Ewing Sarcoma |
Metastatic Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05574504 | — | P2 | withdrawn | Phase II Trial of Lurbinectedin Combined With Avelumab as Switch Maintenance Firstline Therapy |
Extensive Stage Lung Small Cell Carcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05244239 | — | P1 | recruiting | Palliative Radiotherapy With Lurbinectedin in Patients With Extensive Stage Small Cell Lung Cancer |
Gastrointestinal Malignancies (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05229588 | — | P2 | completed | Lurbinectedin in Patients With Advanced Gastrointestinal Malignancies With DNA Repair Mutations |
Small-Cell Lung Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05091567 | IMforte | P3 | active not recruiting | A Phase III, Open-Label Study of Maintenance Lurbinectedin in Combination With Atezolizumab Compared With Atezolizumab in Participants With Extensive-Stage Small-Cell Lung Cancer |
Metastatic Ewing Sarcoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05042934 | — | P1/P2 | withdrawn | Lurbinectedin With or Without Irinotecan in Treating Patients With Relapsed or High Risk Metastatic Ewing Sarcoma |
SCLC (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04802174 | — | P1/P2 | active not recruiting | Lurbinectedin With Berzosertib, an ATR Kinase Inhibitor in Small Cell Cancers and High-Grade Neuroendocrine Cancers |
Platinum-Resistant Lung Small Cell Carcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04607954 | — | P2 | active not recruiting | Durvalumab and Lurbinectedin for the Treatment of Relapsed or Refractory Small Cell Lung Cancer |
Malignant Pleural Mesothelioma, Advanced (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03213301 | — | P2 | completed | Lurbinectedin Monotherapy in Patients With Progressive Malignant Pleural Mesothelioma. |
Solid Tumors (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02451007 | PM01183 | P2 | completed | Evaluation of the Effect of Lurbinectedin (PM01183) on Cardiac Repolarization in Patients With Selected Solid Tumors |
Non-Small Cell Lung Cancer (NSCLC) (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01951157 | PM01183 | P2 | completed | A Clinical Study in Three-arm of Lurbinectedin (PM01183) Alone or in Combination With Gemcitabine and a Control Arm With Docetaxel as Second Line Treatment in Non-Small Cell Lung Cancer (NSCLC) Patients |
Metastatic Breast Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02210364 | PM01183 | P1 | completed | Study of Lurbinectedin (PM01183) in Combination With Capecitabine in Patients With Metastatic Breast Cancer (MBC), Pancreatic Cancer (PC) or Metastatic Colorectal Cancer (CRC). |
Specific Advanced Solid Tumors (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01970553 | — | P1 | completed | Escalating Doses of PM01183 in Combination With Gemcitabine in Patients With Specific Unresectable Solid Tumors |
Endometrial Adenocarcinomas (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01970540 | — | P1 | completed | Study Escalating Doses of PM01183 in Combination With Fixed Doxorubicin in Patients With Specific Advanced Unresectable Solid Tumors |
Lurbinectedin pivotal trial highlights (Phase 2/3/4)
Phase-2/3/4 studies with named acronyms — the registration-grade trials most cited in label discussions and Wikipedia.
| Acronym | NCT | Phase | Status | Indication | Enrollment | PubMed |
|---|---|---|---|---|---|---|
| SaLuDo | NCT06088290 | P3 | active not recruiting | Leiomyosarcoma | 455 | — |
| IDeate-Lung02 | NCT06203210 | P3 | recruiting | Small Cell Lung Cancer | 540 | — |
| DeLLphi-304 | NCT05740566 | P3 | active not recruiting | Small Cell Lung Cancer (SCLC) | 509 | — |
| IMforte | NCT05091567 | P3 | active not recruiting | Small-Cell Lung Cancer | 660 | — |
| LAGOON | NCT05153239 | P3 | completed | Relapsed Small Cell Lung Cancer | 705 | — |
| ATLANTIS | NCT02566993 | P3 | completed | Small-cell Lung Cancer | 613 | — |
| CORAIL | NCT02421588 | P3 | completed | Ovarian Cancer | 442 | — |
| SEZanne | NCT07155174 | P2 | recruiting | Small Cell Lung Cancer | 180 | — |
| ISG-TULIPS | NCT07328425 | P2 | recruiting | Desmoplastic Small Round Cell Tumor | 20 | — |
| LASER | NCT06228066 | P2 | recruiting | Small Cell Carcinoma of the Bladder | 45 | — |
| LURBIMUNE | NCT05572476 | P2 | withdrawn | Small Cell Lung Cancer | 0 | — |
| JAZZ EMERGE201 | NCT05126433 | P2 | terminated | Advanced Solid Tumor | 47 | — |
| PM01183 | NCT02454972 | P2 | completed | Advanced Solid Tumors | 345 | — |
| PM01183 | NCT01951157 | P2 | completed | Non-Small Cell Lung Cancer (NSCLC) | 69 | — |
| PM01183 | NCT02451007 | P2 | completed | Solid Tumors | 39 | — |
Terminated and withdrawn Lurbinectedin trials (7)
Studies that ended before completion. Reasons are filed in each trial's ClinicalTrials.gov entry.
- NCT05574504withdrawnPhase II Trial of Lurbinectedin Combined With Avelumab as Switch Maintenance Firstline Therapy
- NCT06217536withdrawnNeoadjuvant Lurbinectedin and Preoperative Radiation for Treating Soft Tissue Sarcomas
- NCT06385548withdrawnEfficacy and Safety Study of Lurbinectedin and Dostarlimab in Cancer Patients: Protocol VHIO21001 - LiDer
- NCT05572476withdrawnLurbinectedin Combined With Durvalumab in Pre-treated Patients With Extensive Stage Small-cell Lung Cancer
- NCT05126433terminatedLurbinectedin Monotherapy in Participants With Advanced or Metastatic Solid Tumors
- NCT04610658terminatedImmune Checkpoint Inhibition With Lurbinectedin Relapsed/Recurrent SCLC
- NCT05042934withdrawnLurbinectedin With or Without Irinotecan in Treating Patients With Relapsed or High Risk Metastatic Ewing Sarcoma
All Lurbinectedin trials (54)
Sorted by most recent activity (completion → start → posted date). Each row links to the trial detail page on Hipa.ai.
| NCT ID | Acronym | Title | Phase | Status | Enrollment | Sponsor | Started |
|---|---|---|---|---|---|---|---|
| NCT07155174 | SEZanne | A Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination With Atezolizumab Versus Standard of Care as First-Line Treatment in Adult Participants With Previously Untreated Extensive Stage Small Cell Lung Cancer | P2 | recruiting | 180 | AbbVie | Nov 2025 |
| NCT04607954 | Durvalumab and Lurbinectedin for the Treatment of Relapsed or Refractory Small Cell Lung Cancer | P2 | active not recruiting | 29 | Mayo Clinic | Dec 2020 | |
| NCT06681220 | Relapsed SCLC | Biomarker Directed Trial of Temozolomide and Stenoparib in Relapsed SCLC | P1/P2 | recruiting | 166 | VA Office of Research and Development | Feb 2026 |
| NCT07141771 | An Umbrella Study of Recurrent, Extensive Stage Small Cell Lung Cancer Based on Molecular Typing | P1/P2 | not yet recruiting | 100 | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Dec 2025 | |
| NCT07328425 | ISG-TULIPS | Clinical Study in Adult and Young Adult Patients With Advanced Desmoplastic Small Round Cell Tumor (DSRCT) ISG-TULIPS | P2 | recruiting | 20 | Italian Sarcoma Group | Nov 2025 |
| NCT07365241 | A Study to Evaluate Adverse Events and Change in Disease Activity of Intravenous ABBV-706 Versus Standard of Care in Adult Participants With Relapsed/Refractory Small Cell Lung Cancer | P3 | not yet recruiting | 531 | AbbVie | Apr 2026 | |
| NCT07121478 | Patients With High-grade Pancreatic Neuroendocrine Tumors | P2 | enrolling by invitation | 46 | National Cancer Center, Korea | Sep 2025 | |
| NCT07153055 | LOTS | Lurbinectedin With Osimertinib in Transformed Small Cell Lung Cancer | P1/P2 | not yet recruiting | 16 | Misty Shields | May 2026 |
| NCT06088290 | SaLuDo | Study of Lurbinectedin in Combination With Doxorubicin Versus Doxorubicin Alone as First-line Treatment in Participants With Metastatic Leiomyosarcoma (SaLuDo) | P3 | active not recruiting | 455 | PharmaMar | Sep 2023 |
| NCT05800587 | Dose Attenuated Chemotherapy in Compromised Patients With Lung Cancer | P2 | recruiting | 280 | Fox Chase Cancer Center | Feb 2023 | |
| NCT06203210 | IDeate-Lung02 | A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer | P3 | recruiting | 540 | Daiichi Sankyo | May 2024 |
| NCT07258147 | Safety and Efficacy of Radiotherapy Combined With Immunochemotherapy in Pre-treated SCLC Patients With Liver Metastases | P2 | not yet recruiting | 30 | Sichuan University | Oct 2026 | |
| NCT05578326 | Study of Trilaciclib and Lurbinectidin | P2 | recruiting | 30 | UNC Lineberger Comprehensive Cancer Center | Oct 2022 | |
| NCT05574504 | Phase II Trial of Lurbinectedin Combined With Avelumab as Switch Maintenance Firstline Therapy | P2 | withdrawn | 0 | AdventHealth | May 2023 | |
| NCT06228066 | LASER | Lurbinectedin With or Without Avelumab in Small Cell Carcinoma of the Bladder (LASER) | P2 | recruiting | 45 | National Cancer Institute (NCI) | Jun 2024 |
| NCT05918640 | LiFFT | Lurbinectedin in FET-Fused Tumors | P1/P2 | recruiting | 63 | Children's Hospital of Philadelphia | Jul 2023 |
| NCT06496048 | Lurbinectedin or in Combination with Irinotecan Versus Topotecan in Patients with Relapsed SCLC | P3 | recruiting | 180 | Luye Pharma Group Ltd. | Sep 2024 | |
| NCT07459634 | A Study of Lurbinectedin in Combination With Durvalumab for the Treatment of Participants With ES-SCLC | P2 | not yet recruiting | 50 | Jazz Pharmaceuticals | Jun 2026 | |
| NCT05734066 | Study of Lurbinectedin Monotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Ewing Sarcoma | P1/P2 | recruiting | 60 | Jazz Pharmaceuticals | May 2023 | |
| NCT05740566 | DeLLphi-304 | Study Comparing Tarlatamab With Standard of Care Chemotherapy in Relapsed Small Cell Lung Cancer | P3 | active not recruiting | 509 | Amgen | May 2023 |
| NCT04802174 | Lurbinectedin With Berzosertib, an ATR Kinase Inhibitor in Small Cell Cancers and High-Grade Neuroendocrine Cancers | P1/P2 | active not recruiting | 37 | National Cancer Institute (NCI) | Jun 2021 | |
| NCT06217536 | Neoadjuvant Lurbinectedin and Preoperative Radiation for Treating Soft Tissue Sarcomas | P1/P2 | withdrawn | 0 | University of California, San Francisco | Oct 2024 | |
| NCT05099666 | Lurbinectedin + Doxorubicin In Leiomyosarcoma | P1/P2 | active not recruiting | 62 | Massachusetts General Hospital | Feb 2022 | |
| NCT05244239 | Palliative Radiotherapy With Lurbinectedin in Patients With Extensive Stage Small Cell Lung Cancer | P1 | recruiting | 22 | Emory University | Jul 2022 | |
| NCT06497530 | Maintenance Lurbinectedin in Combination With Serplulimab for Patients With ES-SCLC | P2 | recruiting | 30 | Guangzhou Institute of Respiratory Disease | Dec 2024 | |
| NCT05636111 | Phase 1b of Lurbinectedin in Combination With Weekly Paclitaxel and Bevacizumab in Platinum-resistant Ovarian Cancer | P1 | recruiting | 34 | M.D. Anderson Cancer Center | Jul 2023 | |
| NCT05876715 | LINNOVATE | LINNOVATE: Lurbinectedin, Ipilimumab and Nivolumab for Soft Tissue Sarcoma | P1/P2 | recruiting | 40 | ERLINDA M GORDON | Jun 2023 |
| NCT05091567 | IMforte | A Phase III, Open-Label Study of Maintenance Lurbinectedin in Combination With Atezolizumab Compared With Atezolizumab in Participants With Extensive-Stage Small-Cell Lung Cancer | P3 | active not recruiting | 660 | Hoffmann-La Roche | Nov 2021 |
| NCT06385548 | LiDer | Efficacy and Safety Study of Lurbinectedin and Dostarlimab in Cancer Patients: Protocol VHIO21001 - LiDer | P1/P2 | withdrawn | 0 | Vall d'Hebron Institute of Oncology | May 2024 |
| NCT05153239 | LAGOON | Clinical Trial of Lurbinectedin as Single-agent or in Combination With Irinotecan Versus Topotecan or Irinotecan in Patients With Relapsed Small-cell Lung Cancer (LAGOON) | P3 | completed | 705 | PharmaMar | Jul 2022 |
| NCT06501976 | An Exploratory Study of Lurbinectedin With Radiotherapy in Locally-advanced SCLC After First-line Therapy | P2 | not yet recruiting | 9 | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Jul 2024 | |
| NCT05229588 | Lurbinectedin in Patients With Advanced Gastrointestinal Malignancies With DNA Repair Mutations | P2 | completed | 8 | HonorHealth Research Institute | Jun 2022 | |
| NCT02611024 | Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid Tumors | P1/P2 | completed | 316 | PharmaMar | May 2016 | |
| NCT05101265 | Clinical Pharmacokinetic Study of Lurbinectedin in Patients With Advanced Solid Tumors and Varying Degrees of Hepatic Impairment | P1 | unknown | 24 | PharmaMar | Mar 2021 | |
| NCT04358237 | LUPER | Lurbinectedin (PM01183) Combined With Pembrolizumab in Small Cell Lung Cancer. | P1/P2 | completed | 28 | Antonio Calles Blanco | Sep 2020 |
| NCT05572476 | LURBIMUNE | Lurbinectedin Combined With Durvalumab in Pre-treated Patients With Extensive Stage Small-cell Lung Cancer | P2 | withdrawn | 0 | Institut Bergonié | Oct 2023 |
| NCT05126433 | JAZZ EMERGE201 | Lurbinectedin Monotherapy in Participants With Advanced or Metastatic Solid Tumors | P2 | terminated | 47 | Jazz Pharmaceuticals | Mar 2022 |
| NCT04638491 | Safety Tolerability Pharmacokinetic and Preliminary Efficacy in Chinese Advanced Solid Tumors Patients | P1 | completed | 32 | Luye Pharma Group Ltd. | Nov 2020 | |
| NCT04610658 | Immune Checkpoint Inhibition With Lurbinectedin Relapsed/Recurrent SCLC | P1 | terminated | 9 | H. Lee Moffitt Cancer Center and Research Institute | Nov 2020 | |
| NCT05285033 | LURBICLIN | RW Effectiveness of Lurbinectedin in Extensive Stage SCLC | — | completed | 312 | Intergroupe Francophone de Cancerologie Thoracique | Apr 2022 |
| NCT05042934 | Lurbinectedin With or Without Irinotecan in Treating Patients With Relapsed or High Risk Metastatic Ewing Sarcoma | P1/P2 | withdrawn | 0 | M.D. Anderson Cancer Center | Sep 2021 | |
| NCT05063318 | PM01183 | Clinical Trial of Lurbinectedin (PM01183) in Patients With Advanced Solid Tumors | P1 | completed | 14 | PharmaMar | Oct 2020 |
| NCT05072106 | Study to Evaluate the Effect of Bosentan on the Pharmacokinetics of Lurbinectedin in Patients With Advanced Solid Tumors | P1 | completed | 11 | PharmaMar | Jan 2021 | |
| NCT03213301 | Lurbinectedin Monotherapy in Patients With Progressive Malignant Pleural Mesothelioma. | P2 | completed | 42 | Swiss Cancer Institute | Sep 2017 | |
| NCT02454972 | PM01183 | Clinical Trial of Lurbinectedin (PM01183) in Selected Advanced Solid Tumors | P2 | completed | 345 | PharmaMar | Aug 2015 |
| NCT04291937 | A Multicenter Expanded Access Treatment Protocol of Lurbinectedin in Previously Treated SCLC in the USA | — | approved for marketing | 0 | Jazz Pharmaceuticals | — | |
| NCT02566993 | ATLANTIS | Clinical Trial of Lurbinectedin (PM01183)/Doxorubicin Versus CAV or Topotecan as Treatment in Patients With Small-Cell Lung Cancer | P3 | completed | 613 | PharmaMar | Aug 2016 |
| NCT02421588 | CORAIL | Clinical Trial of Lurbinectedin (PM01183) in Platinum Resistant Ovarian Cancer Patients | P3 | completed | 442 | PharmaMar | May 2015 |
| NCT01970540 | Study Escalating Doses of PM01183 in Combination With Fixed Doxorubicin in Patients With Specific Advanced Unresectable Solid Tumors | P1 | completed | 122 | PharmaMar | May 2011 | |
| NCT01980667 | PM01183 | Study of Lurbinectedin (PM01183) in Combination With Cisplatin in Patients With Solid Tumors | P1 | completed | 41 | PharmaMar | Jul 2014 |
| NCT01951157 | PM01183 | A Clinical Study in Three-arm of Lurbinectedin (PM01183) Alone or in Combination With Gemcitabine and a Control Arm With Docetaxel as Second Line Treatment in Non-Small Cell Lung Cancer (NSCLC) Patients | P2 | completed | 69 | PharmaMar | Sep 2013 |
| NCT02210364 | PM01183 | Study of Lurbinectedin (PM01183) in Combination With Capecitabine in Patients With Metastatic Breast Cancer (MBC), Pancreatic Cancer (PC) or Metastatic Colorectal Cancer (CRC). | P1 | completed | 81 | PharmaMar | Apr 2013 |
| NCT02451007 | PM01183 | Evaluation of the Effect of Lurbinectedin (PM01183) on Cardiac Repolarization in Patients With Selected Solid Tumors | P2 | completed | 39 | PharmaMar | Aug 2015 |
| NCT01970553 | Escalating Doses of PM01183 in Combination With Gemcitabine in Patients With Specific Unresectable Solid Tumors | P1 | completed | 47 | PharmaMar | May 2011 |
Lurbinectedin clinical trials: frequently asked questions
- How many Lurbinectedin clinical trials are there?
- 54 Lurbinectedin clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 15 are actively recruiting participants. 18 are marked completed.
- Are Lurbinectedin clinical trials recruiting in 2026?
- Yes — 15 Lurbinectedin trials are actively recruiting in 2026, with 66 U.S. sites across 24 states. See the recruiting trials and the per-state site list further down this page.
- What conditions is Lurbinectedin being studied for?
- Lurbinectedin is being studied for Small Cell Lung Cancer, Advanced Solid Tumor, Small-cell Lung Cancer, Relapsed Small Cell Lung Cancer, Advanced Solid Tumors and 68 more. The trials are grouped by indication on this page.
- What phase is Lurbinectedin in?
- Lurbinectedin clinical trials span 9 Phase 3, 19 Phase 2, 11 Phase 1. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.
- Who sponsors Lurbinectedin clinical trials?
- The lead sponsor across the most Lurbinectedin trials is PharmaMar, with 31 additional lead sponsors listed in the data. Each trial row links to the full study detail page including sponsor information.
Sources and methodology
Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming Lurbinectedinas an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.
Last refreshed .
Related pages on Hipa.ai: